Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more ...

BofA raised the firm’s price target on Eli Lilly (LLY) to $950 from $900 and keeps a Buy rating on the shares after the company reported “strong” ...

For the Magnificent 7 group, Q3 earnings are expected to be up 11.5% from the same period last year on 15.4% higher revenues, ...

The stock market has continued to rise. But it's been tricky. Palantir, Robinhood and AMD lead big earnings this week.

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Our Bureau, New Delhi Friday, October 31, 2025, 14:15 Hrs [IST] Cipla Ltd has reported a growth of 3.7% in net profit for the quarter ...

Cipla declined 2.05% to Rs 1,508.90, extending losses for the second straight session after the company announced a management reshuffle involving the replacement of its managing director and global ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...